A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: Subset analysis and implications for trial design

Multiple Sclerosis Journal

Volumn 18, Issue 6, 2012, Pages 843-852

  Fox, Edward ^a   Wynn, Daniel ^b   Cohan, Stanley ^c   Rill, Donna ^d   McGuire, Dawn ^d   Markowitz, Clyde ^e  

^a Central Texas Neurology Consultants   (United States)

^b Neurology MS Center   (United States)

^c MS Center   (United States)

^d Opexa Therapeutics   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

multiple sclerosis; myelin reactive T cells; relapse rate; relapsing remitting; Tovaxin; treatment na ve

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PLACEBO; TOVAXIN; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DIPLOPIA; DISEASE COURSE; DRUG SAFETY; FEMALE; HUMAN; IMMUNOTHERAPY; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INTENTION TO TREAT ANALYSIS; INTERVERTEBRAL DISK DEGENERATION; LIMB FRACTURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; PATIENT SAFETY; RELAPSE; STUDY DESIGN; T LYMPHOCYTE; THERAPY EFFECT;

EID: 84861808820     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511428462     Document Type: Article

References (28)

1. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol. 2009 ; 9: 393-407
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2002 ; 359: 1221-1231
3. Kieseier BC, Hartung HP. Current disease-modifying therapies in multiple sclerosis. Semin Neurol. 2003 ; 23: 133-146
4. Johnson KP. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis. Neurologist. 2007 ; 13: 182-187
5. Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K. Fingolimod for the treatment of relapsing multiple sclerosis. Expert Rev Neurother. 2011 ; 11: 165-183
6. Kieseier BC, Jeffery DR. Chemotherapeutics in the treatment of multiple sclerosis. Ther Adv Neurol Disord. 2010 ; 3: 277-291
7. Hemmer B, Archeolos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci. 2002 ; 3: 291-301
8. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. New Engl J Med. 2000 ; 343: 935-952
9. Vandenbark AA, Abulafia-Lapid R. Autologous T-cell vaccination for multiple sclerosis: a perspective on progress. BioDrugs. 2008 ; 22: 265-273
10. Hellings N, Raus J, Stinissen P. T-cell vaccination in multiple sclerosis: update on clinical application and mode of action. Autoimmun Rev. 2004 ; 3: 267-275
11. Hellings N, Raus J, Stinissen P. T-cell-based immunotherapy in multiple sclerosis: induction of regulatory immune networks by T-cell vaccination. Expert Rev Clin Immunol. 2006 ; 2: 705-716
12. Hong J, Zang YC, Nie H, Zhang JZ. CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. Proc Natl Acad Sci U S A. 2006 ; 103: 5024-5029
13. Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. J Immunol. 2000 ; 164: 4011-4017
14. Loftus B, Newsom B, Montgomery M, et al. Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies. Clin Immunol. 2009 ; 131: 202-215
15. Wang YC, Meyerson L, Tang YQ, Qian N. Statistical methods for the analysis of relapse data in MS clinical trials. J Neurosci. 2009 ; 285: 206-211
16. Stüve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology. 2009 ; 72: 396-401
17. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 ; 358: 676-688
18. Ramtahal J, Jacob A, Das K, Boggild M. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol. 2006 ; 253: 1160-1164
19. Weinstock-Guttman B, Ramanathan M, Zivadinov R. Interferon-beta treatment for relapsing multiple sclerosis. Expert Opin Biol Ther. 2008 ; 8: 1435-1447
20. Prinz M, Kalinke U. New lessons about old molecules: how type I interferons shape Th1/Th17-mediated autoimmunity in the CNS. Trends Mol Med. 2010 ; 16: 379-386
21. Racke MK, Lovett-Racke AE, Karandikar NJ. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology. 2010 ; 74: S25-30
22. Haas J, Korporal M, Balint B, Fritzsching B, Schwarz A, Wildemann B. Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis. J Neuroimmunol. 2009 ; 216: 113-117
23. Siger M, Durko A, Nicpan A, Konarska M, Grudziecka M, Selmaj K. Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity. J Neurol Sci. 2011 ; 303: 50-52
24. Inusah S, Sormani MP, Cofield SS, et al. Assessing changes in relapse rates in multiple sclerosis. Mult Scler. 2010 ; 16: 1414-1421
25. Doerck S, Göbel K, Weise G, et al. Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis. PLoS One. 2010 ; 5: e15478
26. Aharoni R, Kayhan B, Eilam R, Sela M, Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci U S A. 2003 ; 100: 14157-14162
27. Liblau R. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role. J Neurol Sci. 2009 ; 287: S17-23
28. Arnon R, Aharoni R. Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate. J Neural Transm. 2009 ; 116: 1443-1449